Kornimate/medical-research-clean huggingface dataset:
does performing a composite test 3 months post-operatively reduce the risk of failure to return to sport after lateral ankle ligamentoplasty?

Conditions: Ankle Injuries

Summary: ankle sprain is one of the most common pathologies in the general population (between 2.1 and 3.2 per 1000 patients per year). nearly 40% of patients will develop chronic instability in the year following the sprain. we also know that a premature return to sport is a risk factor for developing chronic instability. however, despite the consensus of experts on the subject which have shown the key physiological elements to evaluate before resuming sport, no test or cohort of tests are proposed to allow a safe return to sport by reducing the risks of relapse. some very recent studies have appeared on non-operated subjects but this remains a subject that is still too little studied, where the lack of consensus and objective criteria increases the risk of instability. surgical treatment remains an effective option to reduce the risk of recurrence but failure of the latter can occur in approximately 13-37% of patients depending on the population, due to a relapse or a return to sport which does not correspond to expectations. of the patient. the objective of the study is therefore to evaluate the predictive nature of a composite test (ankle-go) regarding the return to sport at the same level and the risks of recurrence.


Eligibility criteria:
inclusion criteria: * patient with objective chronic ankle instability who has failed medical treatment and undergone lateral ankle ligament repair surgery * patient practicing a sporting activity at least 2 times a week * patient able to read, write and understand french * patient affiliated to a social security scheme exclusion criteria: * minor or over 50 years of age * pregnant or breast-feeding patient * patient under guardianship, deprived of liberty or under court protection * refusal to participate in research * patient unable to understand or give informed consent * patient having undergone associated surgical procedures modifying the postoperative course * patient having undergone revision surgery

Keywords: ligamentoplasty ankle-go test sport return
ssris vs. tcas for depression in als patients

Conditions: Depression; Amyotrophic Lateral Sclerosis

Summary: depression is seen in 9-11% of als patients and adequate and proper treatment is needed. in this study, als patients will be screened for depression using self-reported multiple choice questionnaire. patients who fulfill the criteria for depression based on this screening tool will be evaluated by psychiatrist before inclusion in the study. the investigators will also measure quality of life and functional status by simple questionnaires. the patients will be allocated into two treatment groups to receive either tca or ssri for 12 weeks. patients will be evaluated every 4 weeks and phone calls will be made in between the visits if needed to assess about efficacy and any side effects. if any patient reports having suicidal thoughts on any of these phone calls or clinic visits, he/she will be immediately sent to the er for appropriate management. the investigators will repeat the questionnaires in the clinic visits, and use them in the data analysis to look for any improvement and to compare the two medication classes used in this study. this data may be used later on to do larger studies and help to make standard recommendations in treating depression in als patients.

this study is a 12-week, open-label, non-randomized, pilot clinical intervention trial. this is investigator initiated study.this trial will be done at st louis university als clinic. als patients will be screened for depression using beck depression inventory (bdi-ii) scale. a mental healthcare provider will evaluate the patients scoring 19 or above, before inclusion in the study. quality of life (qol) assessment by questionnaire (mcgill) and als functional rating scale (als-frs) measurement will be done at the baseline. then these patients will be allocated into two treatment groups to receive either tca or ssri medication for 12 weeks based on the clinical judgment (non-randomized). patients will require clinical encounters every 4 weeks and telephone encounters in between the visits to assess the effectiveness of medication and tolerability of the side effects if any. if any patient endorses active suicidal ideation on any of these assessments, he/she will be immediately sent to the er for appropriate management. at 4, 8 and 12-week clinic visits, repeat bdi, qol and als-frs measurement will be done on each patient from both groups and used in the data analysis.

Eligibility criteria:
inclusion criteria: * documented diagnosis of definite or probable als * informed and written consent for enrollment in study * gender: both male and female * age: 25-80 years * bdi score 19 or above * depression diagnosis by mental health provider exclusion criteria: * history of psychotic disorder, premorbid bipolar depression * als-frs score \< 26 * cognitive impairment * currently on ssris or tcas. however if for some reason they are off their treatment, then they can be enrolled in the study after a washout period of 30 days. * currently on other antidepressants such as monoamine oxidase inhibitors (maois), selective norepinephrine re-uptake inhibitors (snris) etc.
critical care results of sars-cov-2 ards by dapsone and standard covid-19 treatment

Conditions: SARS-CoV-2; Hypoxia; ARDS

Summary: abstract background: clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat sars-cov-2 inflammasome. dapsone is useful in the molecular regulation of nod-like receptor family pyrin domain-containing 3 (nlrp3). objective: to study the targeting of nlrp3 itself or up-/downstream factors of the nlrp3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. methods: patients who were on standard covid-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with cimetadine 400 mg three times daily.

we are investigating in prospective ongoing non-randomized case study effects of addition of dapsone 100-200 mg daily in addition to standardized recommended treatment versus a a cohort of patient admitted at our institution since october 2020 versus a group that only received standardized treatment. our primary out comes are decrease in fio2 requirement leading to discharge from hospital and decrease in over all mortality between group treated with only standardized recommended treat versus group with addition of dapsone and cimetadine. an objective criteria of improvement, was used for effectiveness of therapy. a. a reduction in the fio2 requirement and b. a decrease in the progression of hypoxia. we treated the patients with standard covid-19 ards treatment with dapsone 100 mg to target nlrp3 inflammasomes.

Eligibility criteria:
inclusion criteria: 1. all, pcr confirmed cases of covid-19 exclusion criteria: 1. only consenting consenting patients -
measurement of anterior chamber cell grading using ocular coherence tomography

Conditions: Uveitis

Summary: optical coherence tomography (oct) is routinely used in ophthalmic clinical practice. it uses infrared light to image patient's eyes. some patients, such as those with an inflammatory disease called uveitis or those who have just undergone cataract surgery, have intraocular inflammation. this intraocular inflammation commonly manifests as cells that can be seen on routine microscopic clinical examination. however, the only currently available method to quantify this intraocular inflammation is by manually counting on the microscopic clinical examination. the investigators plan to use the oct machine to image patient's eyes. the investigators will then use the images obtained from the oct to objectively quantify the degree of intraocular inflammation.


Eligibility criteria:
inclusion criteria: * age over 18 years old * intervention arm: * active anterior chamber inflammation in at least one eye as diagnosed by clinical exam * one of the following: 1) diagnosis of uveitis or 2) undergone cataract extraction surgery within the previous 30 days * control arm: * no active intraocular inflammation based on clinical exam exclusion criteria: * corneal opacities in the affected eye * anyone judged unable to understand or consent to study participation

Keywords: uveitis optical coherence tomography
the effect of biomechanical scapular mobilization with movement and motor learning

Conditions: Shoulder Impingement Syndrome

Summary: the study about new mobilization technique used in shoulder impingement syndrome patient to increase the range of motion of elevation, decrease the pain, and increasing the function level, this technique is based on normal mechanics that occur inside the joint during certain movement.

the study is about a new technique of mobilization based on normal biomechanics that occurs during the movements of a joint. for example, shoulder abduction or elevation needs the scapula to move upward rotation with posterior tilt and external rotation. moreover, needs glenohumeral (gh) joint glide inferior and posterior these movements occur normally to permit us to elevate our shoulder without any restriction and the full range of motion(rom). so in the patients with shoulder problems and have difficulties reaching full rom of elevation the investigators applied mobilization of scapula toward upward rotation with external rotation and posterior tilt and by using mobilization belt applied posterior and inferior glide to gh joint. however, mobilization techniques have a short-term effect to enhance this effect, the investigators adding a motor learning approach to achieve a long-term effect and prevent recurrent .the investigators applied this technique 3 times per week for 3 weeks.

Eligibility criteria:
inclusion criteria: clinical diagnosis: shoulder impingement syndrome. 1. history of shoulder pain when they elevated their arm. 2. limited range of motion due to the pain. 3. pain localized at the painful point at proximal anterolateral shoulder region or medical diagnosis of shoulder impingement syndrome with at least 2 positive impingement tests including neer, hawkins, or jobe test. exclusion criteria: * fibromyalgia. * fracture, dislocation, or subluxation of the shoulder. * history of trauma. * shoulder surgery. * numbness or tingling in the upper limb. * corticosteroids injection within 1 year. * systemic illness. * ligamentous laxity
albumin use in burn patients

Conditions: Burns

Summary: this is a study of why and how physicians use albumin during the first 72 hours after a burn injury.

while albumin has been a part of burn resuscitation for many years, its use remains varied and controversial. the purpose of this study is to describe the current practices of albumin administration during the first 72 hours after a burn injury. participating sites will collect data on patients with at least a 20% total body surface area (tbsa) burn. information will be recorded on type and extent of burn injury, basic demographic data, co-morbidities, outcomes and, for the first 72 hours post injury, if albumin was used and why, amount of resuscitation fluids and urine output, and use of vasopressors and diuretics. each participating site will retrospectively review 20 charts of consecutive admissions with at least a 20% tbsa burn. in addition, each site will collect data prospectively on 20 more patients with 20% tbsa burns. prospective data is requested in order to capture as close as possible to "real time" the reasons physicians choose to give albumin. no protected health information (phi) will be recorded. data will be analyzed for patterns of albumin use and reasons for albumin administration.

Eligibility criteria:
inclusion criteria: * burn injury, with and without inhalation injury exclusion criteria: * \<20% total body surface area burned * comfort care only for the burn injury

Keywords: burns albumin fluid resuscitation
hrze fasted/fed in newly diagnosed tb

Conditions: Tuberculosis

Summary: who recommends to take tb drugs while fasting: if tb drugs are taken with food, perhaps drug concentrations are too low; on the other hand: if this is not tolerated, drugs could also be taken with food. do lower drug concentrations - with improved adherence to therapy - outweigh the disadvantage of lower drug blood concentrations over time? how exactly do the drug concentrations over time (pharmacokinetics) compare between fasting and fed conditions, especially in the early stage of tb treatment when patients are relatively sick, and relatively poorly tolerate tb drugs?

to evaluate the influence of concomitant food ingestion on the pharmacokinetics of hrze in newly diagnosed tb patients to evaluate the influence of early disease on the pk parameters of hrze in tb patients to compare the pharmacokinetics of hrze in the early stage of disease with the pharmacokinetics of hrze in more stable condition in newly diagnosed tb patients to evaluate adverse events of hrze in tb patients

Eligibility criteria:
inclusion criteria: * patients with tb who are starting with hrze therapy * age \> 18 years old * written informed consent exclusion criteria: * use of antacids, which cannot be discontinued for study days * active, unstable hepatic disease (with jaundice, hrz)

Keywords: tb bioavailability hrze fasting fed
a post-marketing surveillance study on nesinaact® tablet use among type 2 diabetes mellitus participants in korea

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this post marketing surveillance (pms) study is to estimate the proportion of all adverse events (aes) including serious adverse events (saes) and serious adverse drug reactions (sadrs) in participants who are treated for type 2 diabetes mellitus under nesinaact® tablet therapy (alogliptin/pioglitazone) once daily by physicians in the real-world clinical practice setting over a period of 26 weeks.

the drug being tested in this survey is called nesinaact® tablet. a surveillance is planned to examine safety and effectiveness of nesinaact® tablet therapy in participants who are being treated for type 2 diabetes mellitus. the study will enroll approximately 730 patients. the study observes percentage of participants with adverse events (aes) including serious adverse events (saes) and serious adverse drug reactions (sadrs) administered a dose of nesinaact® tablet (alogliptin/pioglitazone) once daily as prescribed by the physician in routine practice over a period of 26 weeks. this multi-center trial is conducted in a total of 19 sites in korea. the data is collected between october 2 2015 to august 30 2019 from the re-examination period up to 26 weeks.

Eligibility criteria:
inclusion criteria: * participants inadequately controlled on diet and exercise. * participants inadequately controlled on metformin alone. * participants inadequately controlled on pioglitazone alone. * participants inadequately controlled on metformin and pioglitazone combination therapy. * participants switching from alogliptin co-administered with pioglitazone. exclusion criteria: * participants treated with study drug outside of the locally approved label in korea. * participants with contraindication for the use of study drug (as described in the korean product label).

Keywords: drug therapy
a trial of shr-1701 in subjects with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a dose-escalation and dose-expansion phase 1 trial to evaluate the safety and tolerability of shr-1701 in subjects with advanced solid tumors.

this is a two-part, open-label, multicenter, non-randomized, dose escalation, phase 1 study of repeated doses of shr-1701 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies.

Eligibility criteria:
inclusion criteria: * diagnosed (histologically or cytologically) with solid tumors * ecog performance status of 0 or 1 at both the screening and baseline visits * life expectancy ≥12 weeks * adequate laboratory parameters * willing and able to comply with clinic visits and study-related procedures * provide signed informed consent exclusion criteria: * known history of hypersensitivity to the study drug * prior malignancy active within the previous 2 years * any investigational or concurrent cancer therapy * history of immunodeficiency including seropositivity * systemic antibiotics treatment for ≥ 7 days before the first dose * a known history of allogeneic organ transplantation
the role of ribose in patients diagnosed with fibromyalgia

Conditions: Fibromyalgia

Summary: the purose of this research study is to determine the potential benefit of d-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

two hundred to three hundred subjects (equally distribued between placebo and d-ribose) between 18-78 years of age will comprise this study. the final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to tid dosing with approximately equal balance between the active and placebo arms.

Eligibility criteria:
inclusion criteria: * previous diagnosis of fibromomyalgia by a md * has been diagnosed with fibromyalgia and are over 18 years of age * does live in the united states exclusion criteria: * does not have severe medication/chemical/supplement sensitivities * does not have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure) * does not have rheumatoid arthritis or gout * previous use of ribose

Keywords: fibromyalgia ribose d-ribose dextrose
evaluation of a patient education program for ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Spondyloarthritis

Summary: long term disease management is essential for ankylosing spondylitis (as), a chronic progressive systemic inflammatory disease of the axial skeleton. extensive information about the disease is a necessary first step. an education program for as was implemented to improve inpatient medical rehabilitation. in a controlled quasi-experimental multicentric study the efficacy of this program was analysed.


Eligibility criteria:
inclusion criteria: * ankylosing spondylitis (as) according to modified new york criteria * early diagnosis criteria for as * essg criteria for spondyloarthritis exclusion criteria: * history of malignant disease during past five years * secondary fibromyalgia syndrome * group integration deficiencies * seminar repeaters
management of postoperative pain after total knee replacement.

Conditions: Postoperative Pain; Knee Replacement Arthroplasty

Summary: the purpose of this study is to compare two methods of postoperative pain management in patients undergoing total knee replacement.

patients undergoing total knee replacement will be assigned at random to receive one of two methods of postoperative pain management. patients assigned to nerve block will receive regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block. patients assigned to periarticular injection will receive periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. additionally, all patients will be given a standardized combination of oral analgesic medications preoperatively and postoperatively. all patients will receive a posterior stabilized total knee replacement through an medial parapatellar approach.

Eligibility criteria:
inclusion criteria: * unilateral primary total knee replacement. * weight 50-125 kg. * age 18-79 years. * intact neurological exam to the surgical lower extremity. * cognitively intact with ability to sign informed consent. exclusion criteria: * renal insufficiency with creatinine \>1.5 mg/dl. * allergy to medication used in the study. * using narcotic medication prior to surgery (morphine equivalents \>=20 mg/day for \>7 days.) * prior open knee surgery with regional anesthesia or periarticular injection for post-operative pain management.
novel non-opioid post-surgical pain treatment in females

Conditions: Acute Pain; Bunionectomy; Toe Fusion

Summary: this study aims to determine if treatment with carbidopa/levodopa and naproxen in females (biological sex) with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days) will reduce pain when compared with females receiving placebo and naproxen.

acute post-surgical pain remains commonly treated with opioids. although such treatments are efficacious, they can lead to opioid dependency. disturbingly, opioid abuse often began as a direct consequence of prescription medications, primarily for pain management, and post-surgical pain management. recent studies in from apkarian lab suggest that the combination of dopamine and non-steroidal anti-inflammatory may be a safe, tolerable and efficacious novel post-surgical pain treatment option. therefore, the main hypothesis is: patients treated with carbidopa/levodopa and naproxen will show a statistically significant decrease in post-surgical pain when compared with control intervention (placebo plus naproxen (250mg)). this will be done through a double-blind, randomized, placebo-controlled, parallel-group trial of the pharmacological treatment carbidopa/levodopa for females (n = 60) undergoing a bunionectomy or toe fusion surgery.

Eligibility criteria:
inclusion criteria: * female with no racial or ethnic restrictions; * 18 to 75 years old; * have a bunionectomy or toe fusion surgery scheduled; * must be able to read, understand, and sign consent form; * generally healthy. exclusion criteria: * chronic neurologic conditions, e.g., parkinson's * pregnancy; * opioids use 60 mg/day oral morphine milligram equivalent.; * use of anticoagulants (low dose asa allowed); * history of gastric ulcer; renal insufficiency or congestive heart failure, * contraindication to study medication as determined by surgeon * any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk * in the judgment of the investigator, unable or unwilling to follow protocol and instructions; * diagnosis of psychological diseases, such as major depression; bipolar disorder.